Next-generation weight-loss drugs are expected within a year.
Credit: PixabayThe next generation of GLP-1 receptor agonist drugs is on the horizon, with new weight-loss and diabetes treatments expected to hit shelves by early next year. These advancements follow the success of drugs like Ozempic and Wegovy, signaling a rapid evolution in obesity and diabetes care.Less than five years after the FDA approved...